CN109535250A - 美洲型prrsv n蛋白单克隆抗体、其制备方法及其应用 - Google Patents
美洲型prrsv n蛋白单克隆抗体、其制备方法及其应用 Download PDFInfo
- Publication number
- CN109535250A CN109535250A CN201811527178.6A CN201811527178A CN109535250A CN 109535250 A CN109535250 A CN 109535250A CN 201811527178 A CN201811527178 A CN 201811527178A CN 109535250 A CN109535250 A CN 109535250A
- Authority
- CN
- China
- Prior art keywords
- prrsv
- monoclonal antibody
- protein
- american type
- type prrsv
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241001135989 Porcine reproductive and respiratory syndrome virus Species 0.000 title claims abstract description 84
- 101710141454 Nucleoprotein Proteins 0.000 title claims abstract description 57
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- 238000001514 detection method Methods 0.000 claims abstract description 19
- 239000000427 antigen Substances 0.000 claims abstract description 13
- 102000036639 antigens Human genes 0.000 claims abstract description 13
- 108091007433 antigens Proteins 0.000 claims abstract description 13
- 206010029174 Nerve compression Diseases 0.000 claims abstract description 7
- 229960005486 vaccine Drugs 0.000 claims abstract description 7
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 2
- 210000004408 hybridoma Anatomy 0.000 claims description 14
- 238000002965 ELISA Methods 0.000 claims description 13
- 210000004027 cell Anatomy 0.000 claims description 13
- 238000011725 BALB/c mouse Methods 0.000 claims description 3
- 101100454807 Caenorhabditis elegans lgg-1 gene Proteins 0.000 claims description 3
- 241001529936 Murinae Species 0.000 claims description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 3
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 3
- 230000009465 prokaryotic expression Effects 0.000 claims description 3
- 210000004988 splenocyte Anatomy 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 230000003796 beauty Effects 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 abstract description 12
- 238000011160 research Methods 0.000 abstract description 10
- 208000005342 Porcine Reproductive and Respiratory Syndrome Diseases 0.000 abstract description 6
- 238000011161 development Methods 0.000 abstract description 5
- 108090001074 Nucleocapsid Proteins Proteins 0.000 abstract description 3
- 230000010460 detection of virus Effects 0.000 abstract description 2
- 238000000034 method Methods 0.000 description 18
- 238000000746 purification Methods 0.000 description 14
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 12
- 108090000765 processed proteins & peptides Proteins 0.000 description 12
- 238000012797 qualification Methods 0.000 description 11
- 206010003445 Ascites Diseases 0.000 description 10
- 239000007788 liquid Substances 0.000 description 10
- 241000282898 Sus scrofa Species 0.000 description 9
- 229920001184 polypeptide Polymers 0.000 description 8
- 102000004196 processed proteins & peptides Human genes 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 230000003053 immunization Effects 0.000 description 6
- 238000013461 design Methods 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 231100000614 poison Toxicity 0.000 description 5
- 239000002574 poison Substances 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 241001673669 Porcine circovirus 2 Species 0.000 description 4
- 150000001413 amino acids Chemical group 0.000 description 4
- 210000003719 b-lymphocyte Anatomy 0.000 description 4
- 230000007910 cell fusion Effects 0.000 description 4
- LXWYCLOUQZZDBD-LIYNQYRNSA-N csfv Chemical compound C([C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)[C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(O)=O)C1=CC=C(O)C=C1 LXWYCLOUQZZDBD-LIYNQYRNSA-N 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 239000008267 milk Substances 0.000 description 4
- 210000004080 milk Anatomy 0.000 description 4
- 235000013336 milk Nutrition 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 241001494479 Pecora Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- JSQIXEHORHLQEE-MEYUZBJRSA-N His-Phe-Thr Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O JSQIXEHORHLQEE-MEYUZBJRSA-N 0.000 description 2
- 102100034014 Prolyl 3-hydroxylase 3 Human genes 0.000 description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 235000011130 ammonium sulphate Nutrition 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 235000019628 coolness Nutrition 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- GTDOPRQDTRLYAL-UHFFFAOYSA-N hydrogen peroxide;methanol Chemical compound OC.OO GTDOPRQDTRLYAL-UHFFFAOYSA-N 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000009182 swimming Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- -1 that is Proteins 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- RRBGTUQJDFBWNN-MUGJNUQGSA-N (2s)-6-amino-2-[[(2s)-6-amino-2-[[(2s)-6-amino-2-[[(2s)-2,6-diaminohexanoyl]amino]hexanoyl]amino]hexanoyl]amino]hexanoic acid Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(O)=O RRBGTUQJDFBWNN-MUGJNUQGSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- CJQAEJMHBAOQHA-DLOVCJGASA-N Ala-Phe-Asn Chemical compound C[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(=O)N)C(=O)O)N CJQAEJMHBAOQHA-DLOVCJGASA-N 0.000 description 1
- LSMDIAAALJJLRO-XQXXSGGOSA-N Ala-Thr-Glu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(O)=O LSMDIAAALJJLRO-XQXXSGGOSA-N 0.000 description 1
- VNFWDYWTSHFRRG-SRVKXCTJSA-N Arg-Gln-Leu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(O)=O VNFWDYWTSHFRRG-SRVKXCTJSA-N 0.000 description 1
- BTJVOUQWFXABOI-IHRRRGAJSA-N Arg-Lys-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCNC(N)=N BTJVOUQWFXABOI-IHRRRGAJSA-N 0.000 description 1
- DQTIWTULBGLJBL-DCAQKATOSA-N Asn-Arg-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(=O)N)N DQTIWTULBGLJBL-DCAQKATOSA-N 0.000 description 1
- PCKRJVZAQZWNKM-WHFBIAKZSA-N Asn-Asn-Gly Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(O)=O PCKRJVZAQZWNKM-WHFBIAKZSA-N 0.000 description 1
- WPOLSNAQGVHROR-GUBZILKMSA-N Asn-Gln-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC(=O)N)N WPOLSNAQGVHROR-GUBZILKMSA-N 0.000 description 1
- YUOXLJYVSZYPBJ-CIUDSAMLSA-N Asn-Pro-Glu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O YUOXLJYVSZYPBJ-CIUDSAMLSA-N 0.000 description 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
- 206010011703 Cyanosis Diseases 0.000 description 1
- LMXOUGMSGHFLRX-CIUDSAMLSA-N Cys-Gln-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CS)N LMXOUGMSGHFLRX-CIUDSAMLSA-N 0.000 description 1
- SRIRHERUAMYIOQ-CIUDSAMLSA-N Cys-Leu-Ser Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O SRIRHERUAMYIOQ-CIUDSAMLSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241001198387 Escherichia coli BL21(DE3) Species 0.000 description 1
- CITDWMLWXNUQKD-FXQIFTODSA-N Gln-Gln-Asn Chemical compound C(CC(=O)N)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)N)C(=O)O)N CITDWMLWXNUQKD-FXQIFTODSA-N 0.000 description 1
- VSXBYIJUAXPAAL-WDSKDSINSA-N Gln-Gly-Ala Chemical compound OC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](N)CCC(N)=O VSXBYIJUAXPAAL-WDSKDSINSA-N 0.000 description 1
- YPFFHGRJCUBXPX-NHCYSSNCSA-N Gln-Pro-Val Chemical compound CC(C)[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCC(N)=O)C(O)=O YPFFHGRJCUBXPX-NHCYSSNCSA-N 0.000 description 1
- NYCVMJGIJYQWDO-CIUDSAMLSA-N Gln-Ser-Arg Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O NYCVMJGIJYQWDO-CIUDSAMLSA-N 0.000 description 1
- UGVQELHRNUDMAA-BYPYZUCNSA-N Gly-Ala-Gly Chemical compound [NH3+]CC(=O)N[C@@H](C)C(=O)NCC([O-])=O UGVQELHRNUDMAA-BYPYZUCNSA-N 0.000 description 1
- GGEJHJIXRBTJPD-BYPYZUCNSA-N Gly-Asn-Gly Chemical compound NCC(=O)N[C@@H](CC(N)=O)C(=O)NCC(O)=O GGEJHJIXRBTJPD-BYPYZUCNSA-N 0.000 description 1
- PDUHNKAFQXQNLH-ZETCQYMHSA-N Gly-Lys-Gly Chemical compound NCCCC[C@H](NC(=O)CN)C(=O)NCC(O)=O PDUHNKAFQXQNLH-ZETCQYMHSA-N 0.000 description 1
- PTIIBFKSLCYQBO-NHCYSSNCSA-N Gly-Lys-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)CN PTIIBFKSLCYQBO-NHCYSSNCSA-N 0.000 description 1
- VEPBEGNDJYANCF-QWRGUYRKSA-N Gly-Lys-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CCCCN VEPBEGNDJYANCF-QWRGUYRKSA-N 0.000 description 1
- ZKJZBRHRWKLVSJ-ZDLURKLDSA-N Gly-Thr-Cys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)CN)O ZKJZBRHRWKLVSJ-ZDLURKLDSA-N 0.000 description 1
- WIZPFZKOFZXDQG-HTFCKZLJSA-N Ile-Ile-Ala Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O WIZPFZKOFZXDQG-HTFCKZLJSA-N 0.000 description 1
- WLRJHVNFGAOYPS-HJPIBITLSA-N Ile-Ser-Tyr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)N WLRJHVNFGAOYPS-HJPIBITLSA-N 0.000 description 1
- APFJUBGRZGMQFF-QWRGUYRKSA-N Leu-Gly-Lys Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCCCN APFJUBGRZGMQFF-QWRGUYRKSA-N 0.000 description 1
- IZPVWNSAVUQBGP-CIUDSAMLSA-N Leu-Ser-Asp Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O IZPVWNSAVUQBGP-CIUDSAMLSA-N 0.000 description 1
- NCTDKZKNBDZDOL-GARJFASQSA-N Lys-Asn-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCCCN)N)C(=O)O NCTDKZKNBDZDOL-GARJFASQSA-N 0.000 description 1
- MRWXLRGAFDOILG-DCAQKATOSA-N Lys-Gln-Gln Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O MRWXLRGAFDOILG-DCAQKATOSA-N 0.000 description 1
- WBSCNDJQPKSPII-KKUMJFAQSA-N Lys-Lys-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(O)=O WBSCNDJQPKSPII-KKUMJFAQSA-N 0.000 description 1
- MSSABBQOBUZFKZ-IHRRRGAJSA-N Lys-Pro-His Chemical compound C1C[C@H](N(C1)C(=O)[C@H](CCCCN)N)C(=O)N[C@@H](CC2=CN=CN2)C(=O)O MSSABBQOBUZFKZ-IHRRRGAJSA-N 0.000 description 1
- MPCKIRSXNKACRF-GUBZILKMSA-N Met-Pro-Asn Chemical compound CSCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(N)=O)C(O)=O MPCKIRSXNKACRF-GUBZILKMSA-N 0.000 description 1
- KZNQNBZMBZJQJO-UHFFFAOYSA-N N-glycyl-L-proline Natural products NCC(=O)N1CCCC1C(O)=O KZNQNBZMBZJQJO-UHFFFAOYSA-N 0.000 description 1
- 101150082475 ORF7 gene Proteins 0.000 description 1
- WWPAHTZOWURIMR-ULQDDVLXSA-N Phe-Pro-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CC1=CC=CC=C1 WWPAHTZOWURIMR-ULQDDVLXSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000006399 Premature Obstetric Labor Diseases 0.000 description 1
- 206010036600 Premature labour Diseases 0.000 description 1
- FNGOXVQBBCMFKV-CIUDSAMLSA-N Pro-Ser-Glu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(O)=O FNGOXVQBBCMFKV-CIUDSAMLSA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000018569 Respiratory Tract disease Diseases 0.000 description 1
- AEGUWTFAQQWVLC-BQBZGAKWSA-N Ser-Gly-Arg Chemical compound [H]N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(O)=O AEGUWTFAQQWVLC-BQBZGAKWSA-N 0.000 description 1
- CJINPXGSKSZQNE-KBIXCLLPSA-N Ser-Ile-Gln Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(O)=O CJINPXGSKSZQNE-KBIXCLLPSA-N 0.000 description 1
- KCGIREHVWRXNDH-GARJFASQSA-N Ser-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CO)N KCGIREHVWRXNDH-GARJFASQSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- QWMPARMKIDVBLV-VZFHVOOUSA-N Thr-Cys-Ala Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CS)C(=O)N[C@@H](C)C(O)=O QWMPARMKIDVBLV-VZFHVOOUSA-N 0.000 description 1
- GUZGCDIZVGODML-NKIYYHGXSA-N Thr-Gln-His Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N)O GUZGCDIZVGODML-NKIYYHGXSA-N 0.000 description 1
- 101710110895 Uncharacterized 7.3 kDa protein in cox-rep intergenic region Proteins 0.000 description 1
- HNWQUBBOBKSFQV-AVGNSLFASA-N Val-Arg-His Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N HNWQUBBOBKSFQV-AVGNSLFASA-N 0.000 description 1
- FOADDSDHGRFUOC-DZKIICNBSA-N Val-Glu-Phe Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)N FOADDSDHGRFUOC-DZKIICNBSA-N 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 108010044940 alanylglutamine Proteins 0.000 description 1
- 108010047495 alanylglycine Proteins 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 238000011091 antibody purification Methods 0.000 description 1
- GEWYFWXMYWWLHW-UHFFFAOYSA-N azanium;octanoate Chemical compound [NH4+].CCCCCCCC([O-])=O GEWYFWXMYWWLHW-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 108010063718 gamma-glutamylaspartic acid Proteins 0.000 description 1
- 108010089804 glycyl-threonine Proteins 0.000 description 1
- 108010010147 glycylglutamine Proteins 0.000 description 1
- 108010015792 glycyllysine Proteins 0.000 description 1
- 108010077515 glycylproline Proteins 0.000 description 1
- 108010028295 histidylhistidine Proteins 0.000 description 1
- 108010092114 histidylphenylalanine Proteins 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 108010064235 lysylglycine Proteins 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 229960002446 octanoic acid Drugs 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 108010051242 phenylalanylserine Proteins 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 208000026440 premature labor Diseases 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108010031719 prolyl-serine Proteins 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000013138 pruning Methods 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000007974 sodium acetate buffer Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 238000002525 ultrasonication Methods 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000000304 virulence factor Substances 0.000 description 1
- 230000007923 virulence factor Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2469/00—Immunoassays for the detection of microorganisms
- G01N2469/10—Detection of antigens from microorganism in sample from host
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Public Health (AREA)
- Communicable Diseases (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Tropical Medicine & Parasitology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
本发明公开了一种美洲型PRRSV N蛋白单克隆抗体、其制备方法及其应用,以期研发新型PRRSV疫苗。该单克隆抗体可特异性识别氨基酸序列如SEQ NO.1所示的美洲型PRRSV N蛋白的抗原表位。本发明设计了所述单克隆抗体的制备方法。本发明设计了PRRSV双抗夹心ELISA抗原检测试剂盒,含上述的美洲型PRRSV N蛋白单克隆抗体,可避免PRRSV感染早期而出现的抗体空白现象,对病毒感染的检测更直观、快速。本发明将所述美洲型PRRSV N蛋白单克隆抗体在免疫学检测中应用。本发明为进一步研究PRRSV核衣壳蛋白结构奠定基础,为研制新型PRRSV疫苗提供帮助,进而为免疫预防PRRS提供了新方向。
Description
技术领域
本发明涉及细胞免疫技术领域,具体涉及一种美洲型PRRSV N蛋白单克隆抗体、其制备方法及其应用。
背景技术
猪繁殖与呼吸综合征(Porcine Reproduetive and Respiratory Syndrome,PRRS)是目前世界养猪业危害最为严重的病毒性疾病。感染 PRRSV 后母猪以生殖障碍为特征,主要表现为早产、晚期流产、死胎、木乃伊胎、发热、厌食等,感染的仔猪表现为呼吸道症状,也有神经症状。其在发病过程中会出现两耳皮肤发绀发紫,故又称为“蓝耳病”。接触感染、精液传播、空气传播是PRRSV的主要传播途径,鸟类、鼠类、人类等运输工其都可能成为本病的媒介。猪繁殖与呼吸综合征病毒(PRRSV)是引起该病的致病因子。该病毒有两种主要的血清型类型,分别是基因Ⅰ型(欧洲型)和Ⅱ型(美洲型)。欧洲型以 Lelystad 株(LV 株)为代表,美洲型以 VR2332 株为代表。感染PRRSV的猪和感染后康复的猪都能排毒,有研究报道能分别从感染后210天的血清、42天的唾液、43-92天的精液、38天的粪便、21天的鼻腔液、28天的尿液、157天的口腔刮脱物中分离到病毒。
酶联免疫吸附法(Enzyme-linked immunosorbent assay,ELISA)是一种广泛应用在测定液体样本中的蛋白、抗体或激素的免疫分析技术,具有灵敏、特异、简单、快速、稳定及易于自动化操作等特点,适用于量大临床标本的同时检测。目前国内外己经建立了很多关于PRRSV感染检测的ELISA方法,但这些检测方法绝大多数都是基于PRRSV抗体检测的,而猪感染PRRSV后最早7天才能诱发可检测的抗体,个别猪甚至感染PRRSV 3周后仍然检测不到抗体,这种不能及时检出PRRSV感染的状况给后续采取措施来控制PRRS的大面积爆发造成了一定阻碍。
此外,国内外对于PRRSV N蛋白表位的研究并不是非常完善,Meulenberg等人用肽扫描技术对PRRSV I型N蛋白表位进行分析,得到2-12,25-30,40-463段B细胞表位;多年后,Plagemann等人用基于肽扫描方法对PRRSV II型N蛋白表位进行分析,得到23-33,31-50,43-563段B细胞表位;T.Q.An等用噬菌体展示技术结合生物套选法对PRRSV II型N蛋白表位进行分析,获得表位78-87。
研究筛选出合适的靶抗原并制备出相应抗体,以研制新型PRRSV疫苗是免疫预防PRRS的研究重点。
发明内容
本发明要解决的技术问题是提供一种美洲型PRRSV N蛋白单克隆抗体、其制备方法及其应用,以期研发新型PRRSV疫苗。
为解决上述技术问题,本发明采用如下技术方案:
研发一种美洲型PRRSV N蛋白单克隆抗体,所述单克隆抗体能特异性识别美洲型PRRSVN蛋白的抗原表位,所述抗原表位的氨基酸序列如SEQ NO.1所示。
优选的,所述单克隆抗体的重链型为:lgG1,轻链型为:Kappa 型。
优选的,所述单克隆抗体的效价大于等于1:3.2×105。
优选的,所述单克隆抗体IPMA与IFA检测能够特异性识别美洲型PRRSV的不同毒株。
进一步的,所述美洲型PRRSV毒株为JX-A1或BJ-4。
设计一种所述美洲型PRRSV N蛋白单克隆抗体的制备方法,包括以下步骤:
(1)原核表达N蛋白并纯化;
(2)将所述纯化的N蛋白免疫BALB/c小鼠;
(3)融合所述小鼠免疫脾细胞与小鼠骨髓瘤细胞,采用ELISA筛选得阳性杂交瘤细胞;
(5)对阳性克隆进行克隆化培养,得N蛋白单克隆抗体杂交瘤细胞株;
(6)将所述杂交瘤细胞株注射于小鼠腹腔生产所述美洲型PRRSV N蛋白单克隆抗体。
设计一种PRRSV双抗夹心ELISA抗原检测试剂盒,其特征在于,含上述的美洲型PRRSV N蛋白单克隆抗体。
将所述美洲型PRRSV N蛋白单克隆抗体在免疫学检测中应用。
优选的,所述免疫学检测为ELISA、IPMA、IFA中的任意一种。
设计一种含所述的抗体的预防美洲型PRRSV疫苗。
与现有技术相比,本发明的有益技术效果在于:
1. 本发明应用于检测或预防治疗当中,成本低,不依赖于大型仪器;与荧光定量PCR相比,能够显著降低成本,易于在生产和科研中推广和应用。
2. 本发明美洲型PRRSV N蛋白单克隆抗体可特异性的识别N蛋白B细胞新表位。
3. 本发明中的试纸条基于双抗夹心ELISA抗原检测法的原理针对PRRSV抗原的检测,可避免PRRSV感染早期而出现的抗体空白现象,对病毒感染的检测更直观、快速。
4. 本发明中的美洲型PRRSV N蛋白单克隆抗体能够特异性识别美洲型PRRSV的不同毒株,且不与CSFV、PCV2等其他病毒发生交叉反应,可用于制备美洲型PRRSV抗原检测试剂盒。
5. 本发明为进一步研究PRRSV核衣壳蛋白结构奠定基础,为研制新型PRRSV疫苗提供帮助,进而为免疫预防PRRS提供了新的方向和技术基础。
附图说明
图1为pET-28a-N重组载体构建后PCR鉴定结果图;
图中,M为DNA分子质量标准;1为ORF7基因;
图2为PRRSV N蛋白表达及纯化SDS-PAGE鉴定结果图;
图中,M为蛋白分子质量标准;方框标出为N蛋白;
图3为纯化后N蛋白与PRRSV阳性猪血清反应western-blot鉴定结果图;
图中,M为蛋白预染marker;方框标出为阳性猪血清所识别的N蛋白;
图4为单抗与PRRSV JX-A1株的结合能力IPMA鉴定结果图;
图中,1G4、1C6、3D11为单抗上清;PC为阳性血清,作为阳性对照;NC为PBS,作为阴性对照;BC为未接毒空白对照;
图5为覆盖N蛋白重叠多肽的设计图;
图中,分别合成6段多肽,命名P1~P6;
图6为单抗识别位点dot-ELISA鉴定结果图;
图中,P1~P6为合成的短肽,其中P1为经PBS稀释的短肽MPNNNGKQQKKKKGN(1~15aa);PC为经PBS稀释的N蛋白,作为阳性对照;NC为经PBS稀释的原核表达无关蛋白,作为阴性对照;
图7为表位1~15aa在不同毒株间的保守性生物信息学软件分析结果图;
图8为单抗1G4腹水纯化前后SDS-PAGE鉴定结果图;
图中,M为蛋白分子质量标准;1为IG4腹水纯化前;2为IG4腹水纯化后;
图9为单抗1G4腹水纯化后效价结果图;
图10为单抗1G4与PRRSV JX-A1、BJ-4株的结合能力IFA鉴定结果图;
图11为双抗夹心ELISA结果图;
图中,包被物为纯化后的阳性猪IgG;检测物分别为PBS、PRRSV、CSFV、PCV2;单抗为1G4。
具体实施方式
下面结合附图和实施例来说明本发明的具体实施方式,但以下实施例只是用来详细说明本发明,并不以任何方式限制本发明的范围。
在以下实施例中所涉及的仪器设备如无特别说明,均为常规仪器设备;所涉及的试剂如无特别说明,均为市售常规试剂;所涉及的试验方法,如无特别说明,均为常规方法。
实施例一:免疫原的选择和制备
1.免疫原的选择
发明人长期、大量研究、实践、试验发现:首先,在PRRSV基因组所编码的蛋白中,由ORF7编码的核衣壳蛋白即N蛋白高度保守;其次,在机体中由N蛋白激发的免疫反应性远远高于其他蛋白,从而容易获得高亲和力的单抗;再次,PRRSV感染机体后N蛋白含量最高,所占结构蛋白总量的40%~60%,是PRRSV抗原检测的优势靶标。
基于以上三点N蛋白成为首选靶标蛋白。
2.免疫原的制备
N蛋白的核苷酸序列在Genebank上的登录号为:EF112445。
(1)构建表达N蛋白的pET-28a-N重组载体,构建后PCR鉴定结果如图1所示;
(2)将重组表达载体pET-28a-N电转入感受态细胞E.coli BL21(DE3)中,获得阳性重组大肠杆菌BL21(DE3);
(3)将阳性重组大肠杆菌BL21(DE3)接种于LB培养基中,在IPTG浓度为 1mM的条件下,16℃诱导表达10小时;
(4)收集样品进行超声破碎及Ni柱纯;
(5)将纯化后蛋白经SDS-PAGE电泳和Western blot检测。
鉴定结果显示:
如图2所示,纯化后获得的N蛋白纯度较高;如图3所示,纯化后获得的N蛋白在Westernblot检测中显示出与PRRSV阳性猪血清有较高的结合能力。
实施例二:阳性杂交瘤细胞株的筛选及鉴定
1. 动物免疫
(1)将免疫原N蛋白加入弗氏完全佐剂首次免疫,乳化制成免疫抗原;
(2)通过背部皮下多点注射的方法,免疫4~8周龄的雌性BALB/c小鼠3只,免疫剂量50μg/只;
(3)每隔3周用弗氏不完全佐剂与免疫抗原乳化后以相同的方法和剂量对BALB/c小鼠进行加强免疫;
(4)四免后,细胞融合前3~4天,通过尾静脉注射的方法,用不含佐剂的免疫原对BALB/c小鼠进行超强免疫,免疫剂量是100 μg/只;
(5)多抗血清效价和敏感性测定:
最后一次加强免疫后一周,分别对3只小鼠进行剪尾采血,然后通过间接ELISA法和间接竞争ELISA法分别对3只小鼠多抗血清的效价和敏感性进行测定。结果显示3号鼠的免疫效果最好,效价是1:4000,选择3号鼠进行细胞融合。
2. 细胞融合及单克隆抗体制备
(1)采用聚乙二醇的方法,将免疫小鼠的脾细胞与小鼠骨髓瘤细胞SP2/0按细胞数量8:1的比例进行细胞融合,融合后的细胞用HAT选择培养基进行筛选;
(2)分装在铺有饲养细胞的96孔细胞培养板,置37℃、5% CO2培养箱内培养,于融合后第五天每孔补加培养基50 μl,12天后,以N蛋白或多肽作为包被抗原,通过间接ELISA法对杂交瘤细胞上清测OD值,作为阳性杂交瘤的初筛;
(3)通过有限稀释法对阳性杂交瘤细胞进行3~4次亚克隆筛选,最终获得了3株能稳定分泌抗N蛋白单克隆抗体的杂交瘤细胞株(1G4,1C6,3D11)。
3. 稳定性鉴定
将所建立的单克隆杂交瘤细胞株连续培养3个月并反复液氮冻存复苏,从而鉴定杂交瘤细胞的稳定性。结果显示单克隆杂交瘤细胞株稳定性良好。
4. 免疫过氧化物酶单层细胞试验(IPMA)
IPMA操作过程:
Marc145细胞铺96孔细胞板,待细胞汇合度长至70%左右接毒(PRRSV 强毒株JX-A1)。接毒后1h补加2%胎牛血清的DMEM培养基;48h后固定细胞:弃去96孔板中的培养基,PBST洗2~3次,50uL/孔加-20℃预冷的固定液(乙醇/0.3%双氧水的甲醇),室温静置10~15min;弃去固定液,PBST洗3次,200 μL/孔加脱脂奶,四度过夜封闭;弃去封闭液,PBST洗3次,50 μL /孔,分别加入各单抗,37℃,1h;弃去一抗,PBST洗5~6次,拍干,50 μL /孔加一定倍数稀释的对应二抗(HRP-羊抗鼠酶标二抗),37℃,1h;弃去二抗,ddw洗5~6次,拍干,50 μL /孔,显色10min。(AEC显色液:每1ml ddw依次加A液1滴,B液2滴,C液1滴)。
如图4所示,经IPMA筛选,1G4,1C6,3D11均能与PRRSV JX-A1株反应。
实施例三:单抗识别位点的鉴定
1. PRRSV N蛋白抗原表位的制备
如图5所示,采用肽扫描法设计合成6段多肽,每段多肽5个氨基酸重叠,覆盖整个N蛋白。多肽段氨基酸序列如表1所示。
表1多肽段氨基酸序列
。
2. Dot-ELISA筛选能与抗体结合的短肽
多肽用PBS缓冲液稀释,取2μg在NC膜上点样,完全风干后,用5%脱脂奶封闭,4℃过夜;用所述抗体孵育,37℃ 1h;PBST洗涤3~5次,HRP酶标二抗(1:1000稀释),37℃孵育1h;加入AEC底物显色液,室温显色3min后用去离子水终止显色。
如图6所示,结果显示单抗1G4可以特异性识别表位1~15aa;单抗1C6可以特异性识别表位26~50aa;单抗3D11可以特异性识别表位46~70aa。其中,1G4所识别表位未曾被报道过,是一段由本发明新发现的美洲型PRRSV N蛋白B细胞表位。
3. 分析所得新表位在美洲型PRRSV各毒株之间的保守性
利用生物信息学软件ClustalX2.0分析未被报道过的表位1~15aa在美洲型PRRSV各毒株之间的保守性。
表2 毒株信息
。
结果如图7所示,利用生物信息学软件ClustalX2.0结果显示该表位在美洲型PRRSV各毒株之间保守性较高,与欧洲型序列差异较大,显示单抗1G4可用于区分美洲型及欧洲型PRRSV。
实施例四:1G4腹水的制备、纯化及鉴定
1. 体内诱生腹水法制备单抗
选择经产的雌性Balb/c小鼠,腹腔内注射500μl灭菌石蜡,一周后,再次腹腔内注射获得的单克隆杂交瘤细胞1G4,注射量为2×105个细胞,再过一周后,待小鼠腹部膨大后抽取腹水,离心后取上清,用辛酸硫酸铵法对腹水进行纯化。
2. 抗体的纯化
辛酸-硫酸铵法进行抗体纯化,操作方法如下:
(1)取出冻存的单抗腹水或抗血清,6000 r/min离心30min,获得上清液,用醋酸钠缓冲液(0.06mol/L pH4.8)稀释5倍。
(2)用NaOH(5mol/L)调节pH为4.5,室温缓慢搅拌0.5 h,加正辛酸,最终浓度为25μL/mL。
(3)4℃下6000 r/min离心30min,保留上清。
(4)用中速滤纸过滤得到的上清,并加入10×PBS缓冲液(pH7.4),体积为1/10,混合均匀后调节pH为7.4。
(5)在4℃条件下向混合液中添加固体硫酸铵,添加比例为0.2778 g/ mL,可多次添加,30 min内添加完毕。
(6)6000 r/min离心20min,扔掉上清液。添加起始腹水体积1/3的PBS(pH7.2)进行重悬,4℃下用PBS缓冲液透析24 h,期间换液3~4次,收集mAb,分装,-20℃保存。
单抗1G4腹水纯化前后SDS-PAGE鉴定结果图如图8所示,其中1泳道为纯化前,2泳道为纯化后,箭头指示位置由上而下分别为纯化后抗体重链和轻链位置。
3. 纯化后1G4单抗腹水的鉴定
(1)间接ELISA测定结果如图9所示,结果显示,纯化后1G4单抗上清效价均达到1:3.2×105;
(2)亚型鉴定:用亚型鉴定试剂盒对单抗的亚型进行鉴定,鉴定结果显示1G4单克隆抗体重链型为:lgG1,轻链型为:Kappa 型。
4. 间接免疫荧光试验(IFA)
IFA操作过程:Marc145细胞铺96孔细胞板,待细胞汇合度长至70%左右接毒(PRRSV 强毒株JX-A1、BJ-4)。接毒后1h补加2%胎牛血清的DMEM培养基;48h后固定细胞:弃去96孔板中的培养基,PBST洗2~3次,50 μL/孔加-20℃预冷的固定液(乙醇/0.3%双氧水的甲醇),室温静置10~15min;弃去固定液,PBST洗3次,200 μL/孔加脱脂奶,四度过夜封闭;弃去封闭液,PBST洗3次,50 μL /孔加一定稀释度的一抗(IG4),37℃,1h;弃去一抗,PBST洗5~6次,拍干,50 μL /孔加一定倍数稀释的对应二抗(FITC-羊抗鼠酶标二抗),37℃,1h;弃去二抗,PBST洗5~6次,于荧光显微镜下观察荧光。
结果如图10所示单抗IG4与美洲型PRRSV不同毒株反应均良好。
实施例五:双抗夹心ELISA抗原检测
用纯化的抗PRRSV阳性猪多克隆抗体用CBS缓冲液稀释后包被的酶标板上,37℃孵育3h;5%脱脂奶封闭,37℃ 3h ;PBST洗涤3~5次后分别加入待检样品PBS(不接毒阴性对照)、PRRSV、CSFV、PCV2(5×TCID50)37℃孵育1h;加入单抗1G4,37℃孵育1h;PBST洗涤3~5次后加入本发明单抗37℃孵育1h;洗涤后加入HRP羊抗鼠酶标二抗,37℃孵育1h;洗涤后加底物显色液5min后终止,用酶标仪检测其OD450处的吸光值。
结果如图11所示,图中显示单抗1G4可以识别美洲型PRRSV毒株,不与CSFV、PCV2发生交叉反应,特异性良好,可用于PRRSV双抗夹心ELISA抗原检测试剂盒的制备。
上面结合附图和实施例对本发明作了详细的说明,但是,所属技术领域的技术人员能够理解,在不脱离本发明宗旨的前提下,还可以对上述实施例中的各个具体参数进行变更,形成多个具体的实施例,均为本发明的常见变化范围,在此不再一一详述。
SEQUENCE LISTING
<110> 郑州大学,河南中泽生物工程有限公司
<120> 美洲型PRRSV N蛋白单克隆抗体、其制备方法及其应用
<130> 2018
<160> 6
<170> PatentIn version 3.2
<210> 1
<211> 15
<212> PRT
<213> Animal
<400> 1
Met Pro Asn Asn Asn Gly Lys Gln Gln Lys Lys Lys Lys Gly Asn
1 5 10 15
<210> 2
<211> 20
<212> PRT
<213> Animal
<400> 2
Lys Lys Lys Gly Asn Gly Gln Pro Val Asn Gln Leu Cys Gln Met Leu
1 5 10 15
Gly Lys Ile Ile
20
<210> 3
<211> 25
<212> PRT
<213> Animal
<400> 3
Leu Gly Lys Ile Ile Ala Gln Gln Asn Gln Ser Arg Gly Lys Gly Pro
1 5 10 15
Gly Lys Lys Asn Arg Lys Lys Asn Pro
20 25
<210> 4
<211> 25
<212> PRT
<213> Animal
<400> 4
Arg Lys Lys Asn Pro Glu Lys Pro His Phe Pro Leu Ala Thr Glu Asp
1 5 10 15
Asp Val Arg His His Phe Thr Pro Ser
20 25
<210> 5
<211> 25
<212> PRT
<213> Animal
<400> 5
His Phe Thr Pro Ser Glu Arg Gln Leu Cys Leu Ser Ser Ile Gln Thr
1 5 10 15
Ala Phe Asn Gln Gly Ala Gly Thr Cys
20 25
<210> 6
<211> 25
<212> PRT
<213> Animal
<400> 6
Gly Ala Gly Thr Cys Ala Leu Ser Asp Ser Gly Arg Ile Ser Tyr Thr
1 5 10 15
Val Glu Phe Ser Leu Pro Thr Gln His
20 25
Claims (10)
1.一种美洲型PRRSV N蛋白单克隆抗体,其特征在于,所述单克隆抗体能特异性识别美洲型PRRSV N蛋白的抗原表位,所述抗原表位的氨基酸序列如SEQ NO.1所示。
2.根据权利要求1所述的美洲型PRRSV N蛋白单克隆抗体,其特征在于,所述单克隆抗体的重链型为:lgG1,轻链型为:Kappa 型。
3.根据权利要求1所述的美洲型PRRSV N蛋白单克隆抗体,其特征在于,所述单克隆抗体的效价大于等于1:3.2×105。
4.根据权利要求1所述的美洲型PRRSV N蛋白单克隆抗体,其特征在于,所述单克隆抗体IPMA与IFA检测能够特异性识别美洲型PRRSV的不同毒株。
5.根据权利要求4所述的美洲型PRRSV N蛋白单克隆抗体,其特征在于,所述美洲型PRRSV毒株为JX-A1或BJ-4。
6.一种权利要求1所述美洲型PRRSV N蛋白单克隆抗体的制备方法,其特征在于,包括以下步骤:
(1)原核表达N蛋白并纯化;
(2)将所述纯化的N蛋白免疫BALB/c小鼠;
(3)融合所述小鼠免疫脾细胞与小鼠骨髓瘤细胞,采用ELISA筛选得阳性杂交瘤细胞;
(5)对阳性克隆进行克隆化培养,得N蛋白单克隆抗体杂交瘤细胞株;
(6)将所述杂交瘤细胞株注射于小鼠腹腔生产权利要求1所述美洲型PRRSV N蛋白单克隆抗体。
7.一种PRRSV双抗夹心ELISA抗原检测试剂盒,其特征在于,含有权利要求1所述的美洲型PRRSV N蛋白单克隆抗体。
8.权利要求1所述美洲型PRRSV N蛋白单克隆抗体在免疫学检测中的应用。
9.依据权利要求8的应用,其特征在于,所述免疫学检测为ELISA、IPMA、IFA中的任意一种。
10.一种预防美洲型PRRSV疫苗,含有权利要求1所述美洲型PRRSV N蛋白单克隆抗体。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811527178.6A CN109535250A (zh) | 2018-12-13 | 2018-12-13 | 美洲型prrsv n蛋白单克隆抗体、其制备方法及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811527178.6A CN109535250A (zh) | 2018-12-13 | 2018-12-13 | 美洲型prrsv n蛋白单克隆抗体、其制备方法及其应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN109535250A true CN109535250A (zh) | 2019-03-29 |
Family
ID=65855137
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811527178.6A Pending CN109535250A (zh) | 2018-12-13 | 2018-12-13 | 美洲型prrsv n蛋白单克隆抗体、其制备方法及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109535250A (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109554375A (zh) * | 2018-12-13 | 2019-04-02 | 郑州大学 | 美洲型prrsv n蛋白抗原表位及其应用 |
CN113278593A (zh) * | 2021-05-28 | 2021-08-20 | 华南农业大学 | 一种欧洲型prrsv-n蛋白单克隆抗体及其制备方法与应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103044544A (zh) * | 2011-10-17 | 2013-04-17 | 华中农业大学 | 一种检测高致病性猪繁殖与呼吸综合征病毒的elisa试剂盒及应用 |
CN108845149A (zh) * | 2018-07-05 | 2018-11-20 | 郑州大学 | 同时检测猪繁殖与呼吸综合征病毒和猪瘟病毒的胶体金双联试纸条及其制备方法 |
-
2018
- 2018-12-13 CN CN201811527178.6A patent/CN109535250A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103044544A (zh) * | 2011-10-17 | 2013-04-17 | 华中农业大学 | 一种检测高致病性猪繁殖与呼吸综合征病毒的elisa试剂盒及应用 |
CN108845149A (zh) * | 2018-07-05 | 2018-11-20 | 郑州大学 | 同时检测猪繁殖与呼吸综合征病毒和猪瘟病毒的胶体金双联试纸条及其制备方法 |
Non-Patent Citations (1)
Title |
---|
NING LI,HONGLIANG LIU,YAYUN PENG,YATING KOU,AIPING WANG: "An Unique Epitope Recognized by Monoclonal Antibody against HP-PRRSV N: Deep Understanding of Antigenic Structure and Virus-Antibody Interaction", 《第十三届全国免疫学学术大会壁报交流集》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109554375A (zh) * | 2018-12-13 | 2019-04-02 | 郑州大学 | 美洲型prrsv n蛋白抗原表位及其应用 |
CN113278593A (zh) * | 2021-05-28 | 2021-08-20 | 华南农业大学 | 一种欧洲型prrsv-n蛋白单克隆抗体及其制备方法与应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101661042B (zh) | 猪繁殖与呼吸综合征病毒双抗体夹心elisa试剂盒 | |
CN112552396B (zh) | 抗非洲猪瘟病毒p54蛋白单克隆抗体、制备方法及应用 | |
CN111793128B (zh) | 抗非洲猪瘟病毒CD2v蛋白的单克隆抗体及其应用 | |
CN107099506A (zh) | 猪流行性腹泻病毒双抗体夹心elisa定量检测试剂盒及其应用 | |
CN112812178B (zh) | PCV3 Cap蛋白抗原表位肽、抗PCV3 Cap蛋白的单克隆抗体及其制备方法和应用 | |
CN108761098A (zh) | 致病性猪圆环病毒双联抗原快速检测试纸及其制备方法 | |
CN108845149A (zh) | 同时检测猪繁殖与呼吸综合征病毒和猪瘟病毒的胶体金双联试纸条及其制备方法 | |
CN103163299A (zh) | 禽白血病双抗体夹心elisa抗原检测试剂盒 | |
CN105837686A (zh) | 一种单克隆抗体及其应用 | |
CN101294147A (zh) | 抗猪瘟病毒野毒株e2蛋白的单克隆抗体及其制备方法和应用 | |
CN109535250A (zh) | 美洲型prrsv n蛋白单克隆抗体、其制备方法及其应用 | |
CN109180810A (zh) | 特异性结合诺如病毒gi.1基因型vp1蛋白和/或vlp的抗体及其制备方法和应用 | |
Li et al. | Development of an immunochromatographic strip for detection of antibodies against porcine reproductive and respiratory syndrome virus | |
CN115724958A (zh) | 抗诺如病毒gⅱ基因组衣壳蛋白vp1的单克隆抗体及其应用 | |
CN109554375A (zh) | 美洲型prrsv n蛋白抗原表位及其应用 | |
CN108752471A (zh) | 抗pcv2单克隆抗体的制备方法及其应用 | |
Li et al. | A Novel Immunochromatographic Strip Based on Latex Microspheres for the Rapid Detection of North American-Type Porcine Reproductive and Respiratory Syndrome Virus | |
CN116836270B (zh) | 一种抗蓝舌病毒vp7蛋白的单克隆抗体及制备方法与用途 | |
CN104744572B (zh) | 禽和猪戊型肝炎病毒共有抗原、单克隆抗体和制备方法及应用 | |
Zhang et al. | Characterization of monoclonal antibodies against duck hepatitis type 1 virus VP1 protein | |
CN109959788A (zh) | 一种用于检测猪伪狂犬病病毒gE抗体的包被抗原和酶标抗体及阻断法试剂盒 | |
CN109374886B (zh) | 牛传染性鼻气管炎病毒抗体检测试剂盒及其应用 | |
Zhou et al. | Generation of internal image monoclonal anti-idiotypic antibodies against idiotypic antibodies to GP5 antigen of porcine reproductive and respiratory syndrome virus | |
CN113817054B (zh) | 一种特异性结合猪轮状病毒vp6蛋白的鼠单克隆抗体5b11及其应用 | |
CN116655779A (zh) | 新型冠状病毒抗体及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190329 |
|
RJ01 | Rejection of invention patent application after publication |